IBDEI2P4 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45246,1,4,0)
 ;;=4^R63.3
 ;;^UTILITY(U,$J,358.3,45246,2)
 ;;=^5019541
 ;;^UTILITY(U,$J,358.3,45247,0)
 ;;=R63.4^^200^2240^29
 ;;^UTILITY(U,$J,358.3,45247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45247,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,45247,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,45247,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,45248,0)
 ;;=R63.5^^200^2240^28
 ;;^UTILITY(U,$J,358.3,45248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45248,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,45248,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,45248,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,45249,0)
 ;;=R64.^^200^2240^46
 ;;^UTILITY(U,$J,358.3,45249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45249,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,45249,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,45249,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,45250,0)
 ;;=R68.3^^200^2240^51
 ;;^UTILITY(U,$J,358.3,45250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45250,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,45250,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,45250,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,45251,0)
 ;;=R73.01^^200^2240^89
 ;;^UTILITY(U,$J,358.3,45251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45251,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,45251,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,45251,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,45252,0)
 ;;=R73.02^^200^2240^90
 ;;^UTILITY(U,$J,358.3,45252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45252,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,45252,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,45252,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,45253,0)
 ;;=R73.09^^200^2240^15
 ;;^UTILITY(U,$J,358.3,45253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45253,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,45253,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,45253,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,45254,0)
 ;;=R73.9^^200^2240^84
 ;;^UTILITY(U,$J,358.3,45254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45254,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,45254,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,45254,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,45255,0)
 ;;=R76.11^^200^2240^142
 ;;^UTILITY(U,$J,358.3,45255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45255,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,45255,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,45255,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,45256,0)
 ;;=R79.1^^200^2240^3
 ;;^UTILITY(U,$J,358.3,45256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45256,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,45256,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,45256,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,45257,0)
 ;;=R82.5^^200^2240^69
 ;;^UTILITY(U,$J,358.3,45257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45257,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,45257,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,45257,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,45258,0)
 ;;=R82.6^^200^2240^26
 ;;^UTILITY(U,$J,358.3,45258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45258,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,45258,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,45258,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,45259,0)
 ;;=R82.7^^200^2240^27
 ;;^UTILITY(U,$J,358.3,45259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45259,1,3,0)
 ;;=3^Abnormal Urine Microbiological Findings
 ;;^UTILITY(U,$J,358.3,45259,1,4,0)
 ;;=4^R82.7
 ;;^UTILITY(U,$J,358.3,45259,2)
 ;;=^5019607
